2024-513229-22-00已完成2 期
A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6
Mural Oncology Inc.12 个研究点 分布在 2 个国家目标入组 53 人开始时间: 2024年10月14日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 53
- 试验地点
- 12
- 主要终点
- Centrally-assessed overall response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Cohorts 1 and 2)
研究概览
简要总结
To evaluate the antitumor activity of nemvaleukin as monotherapy or in combination with pembrolizumab by assessment of overall response rate (ORR).
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Patient is >=18 years of age.
- •Patient or patient's legal representative is willing and able to provide written informed consent
- •Patient is willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study
- •The patient must have one of the following: • Cohort 1 (ACM with SC dosing): To have unresectable and/or metastatic cutaneous melanoma. No more than 5 patients with acral melanoma may enroll in this cohort • Cohort 2 (AMM with IV dosing): To have unresectable and/or metastatic mucosal melanoma • Cohort 3 (ACM with less frequent IV dosing): To have unresectable and/or metastatic cutaneous melanoma. No patients with mucosal or acral melanoma may enroll in this cohort. • Cohort 4 (advanced cutaneous melanoma with less frequent IV nemvaleukin dosing in combination with pembrolizumab): Patient has unresectable and/or metastatic cutaneous melanoma. No patients with mucosal or acral melanoma may enroll in this cohort.
- •Patients who have received the following prior therapies: • Cohorts 1 and 2 - Patients who have received anti-PD-[L]1 therapy with or without anti-CTLA-4 therapy, and ≤1 other prior regimen of systemic anti-neoplastic therapy (eg, targeted therapy, chemotherapy). Previous adjuvant and/or neoadjuvant therapy counts as 1 prior regimen. Patients must have experienced objective response (PR or CR by RECIST 1.1 or iRECIST) or stable disease (by RECIST 1.1 or iRECIST) as BOR to anti-PD‑[L]1 therapy. Patients with confirmed progressive disease (by RECIST 1.1 or iRECIST) as best response may be included, if they received anti PD [L]1 therapy for ≥12 weeks (from first dose to last dose). Patients with BRAF mutations may or may not have received prior targeted therapy. • Cohort 3 - Patients who have received anti-PD-[L]1 therapy with or without anti-CTLA-4 therapy or anti-lymphocyte-activation gene 3 (LAG- 3) therapy, and ≤1 other prior regimen of systemic anti-neoplastic therapy (eg, targeted therapy, chemotherapy). Previous adjuvant and/or neoadjuvant therapy counts as 1 prior regimen. Patients must have experienced objective response (PR or CR by RECIST 1.1 or iRECIST) or stable disease (by RECIST 1.1 or iRECIST) as BOR to anti PD‑[L]1 therapy. Patients with confirmed progressive disease (by RECIST 1.1 or iRECIST) as best response may be included, if they received anti-PD-[L]1 therapy for ≥12 weeks (from first dose to last dose). Patients with BRAF mutations may or may not have received prior targeted therapy. • Cohort 4 - Patients must not have received prior systemic anticancer therapy for unresectable or metastatic melanoma. Prior adjuvant and/or neoadjuvant PD-[L]1 treatments are allowed if there is at least 6 months between the last dose and date of recurrence.
- •Cohorts 1, 2, and 3 - Patients who have received prior treatment with talimogene laherparepvec (TVEC) are allowed to enroll provided that last exposure to TVEC was ≥28 days prior to first exposure to nemvaleukin and that all injection-site reactions to TVEC have resolved. TVEC shall not be considered a prior regimen of systemic anti-neoplastic therapy, nor shall it be considered a systemic immunomodulatory agent.
- •Patient has at least one measurable lesion that qualifies as a target lesion based on RECIST 1.
- •Tumor lesions situated in a previously irradiated area, or in an area subjected to other loco regional therapy, are not considered measurable unless there has been demonstrated progression in the lesion.
- •Cohort 1 and Cohort 2 (required); Cohort 3 (optional but recommended if lesions are accessible) and Cohort 4 (may be required for Inclusion 18, otherwise optional but recommended if the lesions are accessible): Patient is willing to undergo a pretreatment tumor biopsy or provide qualifying archival tumor tissue. To qualify, archival tissue must have been sampled after last exposure to any systemic anti-neoplastic agent (including TVEC or anti-PD-L1 therapy whichever is last). Patients in Cohort 1 and Cohort 2 who are unable to undergo a biopsy may be enrolled if risk/benefit ratio of biopsy is considered unfavorable and/or when a biopsy would likely lead to significant delays in care. This decision must be accompanied by supporting documentation from the Investigator and performed in consultation with Medical Monitor. All pretreatment tissue must have been collected no more than 120 days prior to screening.
- •Patient has recovered from the effects of any previous chemotherapy, immunotherapy, other prior systemic anticancer therapy, radiotherapy, and/or surgery (ie, residual toxicity no worse than Grade 1 [Grade 2 treatment-associated peripheral neuropathy and/or any grade of alopecia are acceptable assuming all other inclusion criteria are met]). For immune-related adverse events (AEs) see Exclusion 21
排除标准
- •Patient has uveal melanoma (all cohorts), acral melanoma (Cohort 2, Cohort 3, and Cohort 4), or mucosal melanoma (Cohort 3 and Cohort 4).
- •Patient has active autoimmune disease(s) requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease that has required chronic or frequent systemic steroids. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is allowed.
- •Patient has underlying chronic lung disease, chronic obstructive pulmonary disease, metastatic lung disease, pleural effusions or other lung disorders (eg, pulmonary embolism) with a baseline room air oxygen saturation of <92% at screening, and/or dyspnea (≥Grade 3), which requires oxygen therapy.
- •Patient has any other concurrent uncontrolled illness, including mental illness or substance use, which may interfere with the ability of the patient to cooperate and participate in the study. Other examples of such conditions would include unstable, poorly controlled, or severe hypertension; clinically significant pericardial effusion; New York Heart Association Class III or Class IV congestive heart failure (see Appendix 1); high risk cardiovascular disease, defined as unstable angina, myocardial infarction, or cerebrovascular accident within 6 months of first dose; uncontrolled diabetes mellitus that has required 2 or more hospitalizations in the last year and/or emergent management within the last 6 months; severe peripheral vascular disease; or recent serious trauma.
- •Patient has had an active second malignancy within the previous 2 years. This criterion does not apply to patients with adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, prostate cancer of highest Gleason score ≤6 with undetectable prostatespecific antigen over the previous 12 months, urothelial carcinoma in situ, or ductal carcinoma in situ of the breast that has undergone full surgical resection.
- •Patient is currently pregnant, breastfeeding, or is planning to become pregnant or to begin breastfeeding during the study period or within 30 days (Cohort 1, Cohort 2, and Cohort 3) or 120 days (Cohort 4) after last study drug administration.
- •Patient has active or symptomatic central nervous system (CNS) metastases unless all the following have been met: such metastases have been treated by surgery and/or radiation therapy, and/or gamma knife and have remained radiographically stable (or shrinking) on 2 consecutive imaging examinations performed at least 6 weeks apart; AND steroids have been tapered to a dose of 10 mg of prednisone (or equivalent) or less for at least 2 weeks prior to first dose of study agent(s); AND the patient is neurologically stable. Patients with history of brain metastases or a suspicion of brain metastases must have a brain magnetic resonance imaging at baseline (Screening Visit).
- •Patient has received prior interleukin (IL)-2–based or IL-15–based cytokine therapy; patient has had exposure, including intralesional, to IL-12 or analogs thereof
- •Patient has received radiotherapy within the last 4 weeks before start of study treatment, with the exception of limited field palliative radiotherapy to an area not inclusive of or adjacent to the target lesion(s), that has been completed at least 2 weeks before starting study treatment with no ongoing acute sequelae (eg, radiation burns).
- •Patient requires systemic corticosteroids (>10 mg of prednisone daily, or equivalent) or patient has taken systemic corticosteroids (>10 mg of prednisone daily, or equivalent) within 14 days prior to the first dose of study drug; however, replacement doses, topical, ophthalmologic, and inhalational steroids are permitted.
- •Patient has taken non-steroid systemic immunomodulatory agents (eg, Enbrel®, Humira®, etc) within 28 days prior to the first dose of study drug or anticipates use of these therapies during the study period.
- •Patient has undergone prior solid organ and/or non-autologous hematopoietic stem cell or bone marrow transplant.
- •Patient has received a live or live-attenuated vaccine(s) within 30 days prior to the first dose of study treatment. Note: COVID-19 vaccine is allowed (see Section 8.4.2 for further details).
- •Patient has received more than 3 doses of therapeutic systemic broadspectrum antibiotics within 4 days prior to the first dose of study drug. Antibiotics given for peri-procedural prophylaxis or given presumptively for a limited time (eg, until infection was ruled out), as well as topical or intra-ocular antibiotics, shall not be exclusionary.
- •Patient has had any active infection and/or a fever ≥38.5°C (≥101°F) within 3 days prior to the first dose of study drug.
结局指标
主要结局
Centrally-assessed overall response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Cohorts 1 and 2)
Centrally-assessed overall response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Cohorts 1 and 2)
Investigator-assessed ORR based on RECIST 1.1 (Cohort 3) and Cohort 4
Investigator-assessed ORR based on RECIST 1.1 (Cohort 3) and Cohort 4
次要结局
- Centrally-assessed duration of response (DOR), progression-free survival (PFS), and disease control rate (DCR), and time to response (TTR) based on RECIST 1.1.(Cohorts 1 and 2).
- Investigator-assessed DOR, PFS, DCR, and TTR based on RECIST 1.1(Cohort 3 and Cohort 4)
- Safety and tolerability will be assessed on the basis of treatmentemergent adverse events (TEAEs), vital signs and weight, electrocardiograms (ECGs), and clinical laboratory parameters.
研究者
Mural Oncology, Inc.
Scientific
Mural Oncology Inc.
研究点 (12)
Loading locations...
相似试验
招募中
3 期
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck CancerNCT07276399Janssen Research & Development, LLC500
招募中
2 期
Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard TreatmentNCT07275216City of Hope Medical Center23
招募中
2 期
Pembrolizumab in locally advanced sinonasal carcinoma - NeoPeSino2023-505917-25-00Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb28
招募中
2 期
Pembrolizumab in combination with lenvatinib in patients with recurrent, persistent, metastatic or locally advanced vulvar cancer not amenable to curative surgery or radiotherapy (PIERCE)2024-515646-16-00AGO Research GmbH42
招募中
2 期
Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer2024-517868-33-00Bicycletx Limited30